Skip to content

    Krishna Institu.

    KIMSGood
    Healthcare·13 May 2025
    Management Summary

    KIMS delivered a strong performance in FY25, characterized by robust revenue growth and margin expansion despite the drag from newly commissioned units. The company is in a heavy expansion phase, entering new markets like Maharashtra and Kerala while consolidating its lead in Telangana and Andhra Pradesh. Management is leveraging high-end medical technology (Gamma Knife, TULSA-PRO) to drive ARPOB and expects new units to reach EBITDA break-even within 12 months of commissioning.

    Highlights

    8

    • Full Year FY25 Revenue reached ₹3,067 crores, representing a 22% YoY growth.

    • Q4 FY25 Revenue stood at ₹801 crores, up 25.7% YoY and 1.4% QoQ.

    • FY25 EBITDA Margin improved to 26.6% compared to 26% in FY24.

    • PAT for FY25 increased to ₹415 crores from ₹336 crores in the previous year.

    • Average Revenue Per Operating Bed (ARPOB) grew significantly by 22.7% YoY in FY25.

    • Net Debt as of March 31, 2025, was ₹1,805 crores, with a target to maintain Net Debt to EBITDA at 1:2.

    • Aggressive expansion continues with new units in Nashik, Sangli, Kannur, Kollam, and Guntur now operational.

    • Management noted a unique operational challenge: beefing up security and painting Red Cross symbols on terraces due to national tensions following a massacre in Pahalgam.

    What Changed1

    vs Q1 FY26

    Guidance items5 → 6 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹801 Cr+25.7%YoY
    2. 02EBITDA Margin25.3%-0.2%YoY
    3. 03PAT₹106 Cr+47.2%YoY
    4. 04EPS₹9.6+24%YoY
    5. 05Net Debt₹1,805 Cr

    Segment breakdown

    Telangana Cluster
    65,000 Rs ARPOB50% Occupancy32% EBITDA Margin
    Andhra Pradesh Cluster
    23,500 Rs ARPOB6% IP Volume Growth
    Sunshine Hospitals
    ₹600 Cr FY25 Revenue₹170 Cr FY25 EBITDA
    Nagpur Unit
    ₹100 Cr FY25 Revenue₹40 Cr FY25 EBITDA
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Profitability
    EBITDA Break-even for Nashik and Kerala units
    Positive
    		High
    Debt
    Net Debt
    ₹2,100 crores
    		Medium
    Debt
    Net Debt to EBITDA Ratio
    1:2
    		High
    Capex
    Total Capex Spend
    ₹600-700 crores
    		Medium
    Margin
    ARPOB Growth (Mature Clusters)
    4-5%
    		Medium
    Capacity
    Occupancy (Telangana Cluster)
    65-75%
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Geopolitical/Security Tensions

    Chairman noted the 'war situation' following the Pahalgam massacre, leading to increased security and emergency measures at hospital units. — Management acknowledged

    medium

    Insurance Empanelment Delays

    Nashik and Thane units are currently seeing slower ramp-ups because insurance empanelment is pending, forcing a reliance on cash business. — Both acknowledged

    medium

    Rising Debt Levels

    Net debt is expected to peak at ₹2,100 crores, but management is confident in maintaining a 1:2 Net Debt/EBITDA ratio. — Analyst downplayed

    low

    Areas of Evasion(1)

    • Specific breakdown of tariff hike vs. mix in the 20% ARPOB growth was slightly generalized.

    Q&A highlights

    3

    “The margin expansion is on account of revenue growth... We onboarded a new liver transplant team in Secunderabad because of which there has been significant growth.”

    Explains how high-end specialty mix is driving profitability in mature clusters to offset new unit losses.

    asked by Amey Chalke, JM Financial

    2 min read5 chapters

    Detailed Narrative

    01

    Aggressive Expansion into High-Potential Markets

    KIMS is executing a rapid expansion strategy, having recently opened units in Nashik, Sangli, Kannur, Kollam, and Guntur. The company is also preparing for a major entry into Mumbai (Thane) and Bangalore, with three large hospitals expected to be operational by Q1 FY26. While these new units contributed an EBITDA loss of ₹18.31 crores in FY25, management expects this drag to end by Q1 FY27 as units reach break-even within 12 months.

    02

    Technology and Specialty Mix Driving ARPOB

    The company reported a massive 22.7% growth in ARPOB for FY25, driven by a shift toward high-end specialties like liver transplants and the introduction of advanced medical technology. KIMS is the first in India to introduce TULSA-PRO for prostate treatment and the first in South India to install the Gamma Knife for neurosurgery. These non-invasive, OP-based technologies are expected to drive future ARPOB growth with minimal operational costs.

    03

    Cluster Performance Divergence

    There is a significant gap between the Telangana and Andhra Pradesh clusters. Telangana is a mature, high-margin market with an ARPOB of ₹65,000 and EBITDA margins exceeding 30%. In contrast, the Andhra cluster operates at an ARPOB of ₹23,000-₹24,000 due to a higher component of government schemes. Management aims to improve Andhra's ARPOB to ₹30,000 over the next 3-4 years through better case mix and efficiency.

    04

    Financial Discipline Amidst High Capex

    Despite a planned capex of ₹600-700 crores over the next two years and net debt projected to rise to ₹2,100 crores, KIMS remains committed to financial prudence. The management intends to maintain a Net Debt to EBITDA ratio of 1:2. The CFO noted that most capex for the large Bangalore and Thane projects has already been incurred, and future spending will focus on maintenance and smaller expansions in Srikakulam and Ongole.

    05

    Operational Resilience and Security

    A unique highlight of the call was the management's response to national security tensions. Following the Pahalgam massacre, KIMS implemented emergency protocols, including painting Red Cross symbols on hospital terraces and beefing up security. This demonstrates a high level of operational readiness and sensitivity to external risks that could impact patient safety and facility integrity.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.